Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Do cannabinoids reduce multiple sclerosis-related spasticity?

Thaera GM, Wellik KE, Carter JL, Demaerschalk BM, Wingerchuk DM.

Neurologist. 2009 Nov;15(6):369-71. doi: 10.1097/NRL.0b013e3181bf5572.

PMID:
19901724
2.

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

Trebst C, Stangel M.

Fortschr Neurol Psychiatr. 2005 Aug;73(8):463-9. Review. German.

PMID:
16052440
3.

[Cannabinoids in multiple sclerosis. Opportunity or hazard?].

Neuhaus O, Kieseier BC, Klimke A, Gaebel W, Hohlfeld R, Hartung HP.

Nervenarzt. 2004 Oct;75(10):1022-6. Review. German.

PMID:
15156287
4.

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group..

Lancet. 2003 Nov 8;362(9395):1517-26.

PMID:
14615106
5.

[Cannabinoids for symptomatic therapy of multiple sclerosis].

Husseini L, Leussink VI, Warnke C, Hartung HP, Kieseier BC.

Nervenarzt. 2012 Jun;83(6):695-704. doi: 10.1007/s00115-011-3401-9. Review. German.

PMID:
22080198
6.
7.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
8.

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Pozzilli C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Review.

PMID:
24289844
9.

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group..

Eur J Neurol. 2007 Mar;14(3):290-6.

PMID:
17355549
10.

Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.

Meuth SG, Vila C, Dechant KL.

Expert Rev Neurother. 2015;15(8):909-18. doi: 10.1586/14737175.2015.1067607. Review.

PMID:
26166264
11.

Cannabinoids in multiple sclerosis: do they have a therapeutic role?

Killestein J, Uitdehaag BM, Polman CH.

Drugs. 2004;64(1):1-11. Review.

PMID:
14723555
12.

Towards cannabis and cannabinoid treatment of multiple sclerosis.

Croxford JL, Miller SD.

Drugs Today (Barc). 2004 Aug;40(8):663-76. Review.

PMID:
15510238
13.

Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.

Smith PF.

Curr Opin Investig Drugs. 2002 Jun;3(6):859-64. Review.

PMID:
12137404
14.

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.

Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B.

CMAJ. 2012 Jul 10;184(10):1143-50. doi: 10.1503/cmaj.110837.

15.

Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.

Meinck HM, Schönle PW, Conrad B.

J Neurol. 1989 Feb;236(2):120-2.

PMID:
2709054
16.

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

Bazinski H, Jensen HB, Stenager E.

Ugeskr Laeger. 2015 May 11;177(20):956-60. Review. Danish.

PMID:
26535431
17.

Cannabinoids and multiple sclerosis.

Pertwee RG.

Pharmacol Ther. 2002 Aug;95(2):165-74. Review.

PMID:
12182963
18.

Anti-spasticity agents for multiple sclerosis.

Shakespeare DT, Boggild M, Young C.

Cochrane Database Syst Rev. 2003;(4):CD001332. Review.

PMID:
14583932
19.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.

Podda G, Constantinescu CS.

Expert Opin Biol Ther. 2012 Nov;12(11):1517-31. doi: 10.1517/14712598.2012.721765. Review.

PMID:
22954177
20.

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

Lakhan SE, Rowland M.

BMC Neurol. 2009 Dec 4;9:59. doi: 10.1186/1471-2377-9-59. Review.

Supplemental Content

Support Center